We are thrilled to provide our partners outstanding clinical evidence, now supported with enhanced reimbursement, said Chris Sharp, CEO Human Regenerative Technologies, LLC
El Segundo, CA (PRWEB) November 16, 2016
Human Regenerative Technologies (HRT) Granted High Cost Reimbursement Status for Wound Care Amniotic Membranes under Q4163
Elevated reimbursement status granted by The Center for Medicare & Medicaid (CMS) enables broader patient access to advanced skin substitute.
Human Regenerative Technologies, LLC (HRT®), a leading regenerative biologics processor of placental tissues is pleased to announce the Center for Medicare and Medicaid has granted high-cost reimbursement status for wound care amniotic membrane skin substitutes under Q4163. This status allows for enhanced reimbursement at ambulatory and hospital outpatient facilities, expanding patient access to this next-generation biologic.
High-cost status was granted November 1st 2016, and will go into effect January 1st 2017.
This announcement parallels the release of a pilot study showing accelerated wound closure rates in patients treated with these products. The real-world efficacy of these membranes was demonstrated in patients with large, chronic, non-healing wounds and significant co-morbidities.
“We are thrilled to provide our partners outstanding clinical evidence, now supported with enhanced reimbursement, said Chris Sharp, CEO Human Regenerative Technologies. We hope this new reimbursement status will enable more patients to benefit from this technology.”
WoundEx FastActing Amniotic Membranes are part of an extensive portfolio of placental based biologics from HRT. Utilizing the proprietary HydraTek® Process, HRT provides the highest quality and most diverse line of amniotic and placental based biologics for use in wound care, foot & ankle. urology, podiatry, ob/gyn. orthopedics, spine, plastic surgery and many others.
About Human Regenerative Technologies, LLC (HRT) - Harnessing the Regenerative Power of the Body®:
Human Regenerative Technologies, LLC (HRT®) is a regenerative biologics company, focused on advancing the understanding and development of human cellular and protein-based therapies through scientific and clinical application.
HRT provides the highest quality and has developed the industry’s most diverse line of active amniotic and placental based biologics utilizing our proprietary HydraTek® process for use in wound care, foot & ankle. urology, podiatry, ob/gyn. ENT, orthopedics, spine, plastic surgery.
HRT's commercially available regenerative biologics successfully combine precise science and technology in the procurement, processing and delivery of innovative and novel active Extracellular Matrix (ECM) biologic products derived from human amniotic and placental tissues.
HRT continues to expand its national and international distribution network and private label opportunities with synergistic medical companies.
For more information, visit our website at http://www.humantissue.com or email: info(at)humantissue(dot)com